Alzheimer's Disease: key endpoint results by drug
The key endpoints of Alzheimer's Disease trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Alzheimer's Disease page.
CDR-SB, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| AGB101 | 0.9 | 1.1 | −0.2 | 220 mg · wk 78 · n 81 | NCT03486938 Phase 2/3, primary |
| Donanemab | 1.2 | 1.6 | −0.4 | wk 76 · n 93 | NCT03367403 Phase 2, secondary |
| Emestedastat | 0.3 | 0.2 | +0.1 | wk 12 · n 85 | NCT02727699 Phase 2, secondary |
| Lecanemab | 1.2 | 1.5 | −0.3 | 10 mg/kg Monthly · wk 78 · n 246 | NCT01767311 Phase 2, secondary |
| Masupirdine | 1 | 1.2 | −0.2 | 100 mg · wk 26 · n 176 | NCT02580305 Phase 2, secondary |
| Pegipanermin | 0.2 | 0.3 | −0.1 | 1.0 mg/kg · wk 24 · n 134 | NCT05318976 Phase 2, secondary |
Drugs checked with no result here: 12 not reported, 9 not posted, 11 trial running.
ADAS-Cog11, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Buntanetap | -2.2 | -2.3 | +0.1 | 30 mg · wk 12 · n 79 | NCT05686044 Phase 2/3, primary |
| Hydromethylthionine mesylate | 1.3 | 1.7 | −0.4 | 16 mg/day · wk 52 · n 189 | NCT03446001 Phase 3, primary |
| Masupirdine | 2.5 | 2.6 | −0.1 | 100 mg · wk 26 · n 176 | NCT02580305 Phase 2, primary |
| Tricaprilin | 0.6a | 0 | +0.6 | wk 26 | NCT01741194 Phase 2/3, primary |
Drugs checked with no result here: 13 trial running, 14 not reported, 7 not posted.
ADCS-ADL, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Buntanetap | 0.1 | 2.0 | −1.9 | 30 mg · wk 12 · n 76 | NCT05686044 Phase 2/3, secondary |
| Masitinib | 1.0a | -0.8 | +1.8 | masitinib 4.5 mg/kg/day · wk 24 | NCT01872598 Phase 3, primary |
| Masupirdine | -3.4 | -4.4 | +1 | 100 mg · wk 26 · n 176 | NCT02580305 Phase 2, secondary |
| Sodium oligomannate | -0.5 | -1.1 | +0.6 | 900mg · wk 24 · n 83 | NCT01453569 Phase 2, secondary |
Drugs checked with no result here: 13 trial running, 14 not reported, 7 not posted.
MMSE, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| AGB101 | -2.2 | -1.9 | −0.3 | 220 mg · wk 78 · n 81 | NCT03486938 Phase 2/3, secondary |
| Buntanetap | -1.4 | 1.1 | −2.5 | Low dose · wk 3 · n 5 | NCT02925650 Phase 1/2, secondary |
| Donanemab | -2.4 | -3.0 | +0.6 | wk 76 · n 91 | NCT03367403 Phase 2, secondary |
| Emestedastat | 0.2 | -0.2 | +0.4 | wk 12 · n 86 | NCT02727699 Phase 2, secondary |
| Masupirdine | -1.1 | -1 | −0.1 | 100 mg · wk 26 · n 176 | NCT02580305 Phase 2, secondary |
Drugs checked with no result here: 11 trial running, 13 not reported, 9 not posted.
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 38 approved or late-stage drugs with a featured trial in Alzheimer's Disease were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.